Skip to content

A clinical study on the prevention and treatment of vulvovaginal candidiasis in women with Azmasol

A clinical study on the prevention and treatment of vulvovaginal candidiasis in women with Azmasol

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076392
Enrollment
Unknown
Registered
2023-10-07
Start date
2021-03-10
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vulvovaginal candidiasis

Interventions

oral Azmasol , 2 pills twice a day for 6 days
Treatment group 2:Oral fluconazole 150mg, once a day for 1 day
Treatment group 1:Oral fluconazole 150mg once a day for 1 day and vaginal miconazole 400mg once a night for 3 days
vaginal miconazole 400mg, once a night for 3 days
if symptoms are effectively controlled after 7 days from the first treatment, continue oral Azmasol 1 pill daily for 12 weeks for consolidation.
Treatment group 3:Vaginal miconazole suppositories 400mg once a night for 3 days and oral Azmasol, 2 sticks twice a day for 6 days

Sponsors

Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Healthy women who are sexually active; 2. 18 years of age or older; 3. Have not consumed cranberry juice, polyphenols or antioxidant supplements within the past 2 weeks; 4. = 2 recurrent episodes of vulvovaginal candidiasis in the past 6 months; or 5. = 3 episodes of recurrent vulvovaginal candidiasis in the past 12 months.

Exclusion criteria

Exclusion criteria: 1. Have used antibiotics or cranberry extract within the last two weeks; 2. Have a history of antibiotic allergy; 3. Have a history of cranberry allergy; 4. Are pregnant or in the process of preparing for pregnancy; 5. Patients with kidney stones; 6. With a history of kidney transplantation; 7. Patients with renal tumours.

Design outcomes

Primary

MeasureTime frame
Clinical cure rate;Compound cure rate;

Secondary

MeasureTime frame
Clinical improvement;Microbial clearance;

Countries

China

Contacts

Public ContactDongmei Wei

West China Second Hospital,Sichuan University

dongmeiwei@scu.edu.cn+86 189 8215 0655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026